Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/98.Dcv6mj5a.js ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
The U.S. Food and Drug Administration (FDA) is demanding increased, in-your-face food transparency when it comes to nutrition ...
Read More: Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs ...
Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
Indianapolis-based Eli Lilly and Co. is projecting approval of its experimental weight-loss pill as soon as early 2026, CEO Dave Ricks said, one of several in a new generation of the popular drugs.
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
The U.S. Food and Drug Administration (FDA) recently approved ... Zepbound offers a new approach to managing OSA symptoms while also promoting significant weight loss. Zepbound is an injectable ...